Dimerix awarded second Innovation Connections Grant
23 October 2019 MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage drug development company, announced today that it has been awarded a second Innovation Connections Grant, which is supported by the Australian Government’s Department of Industry, Innovation and…
Dr Jennifer Rosenthal Appointed Clarity Pharmaceuticals Director of Quality and Regulatory Affairs
23 October 2019 Sydney, Australia – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Jennifer Rosenthal as Director of Quality and Regulatory Affairs. Jennifer has more…
SeerPharma Journal October 2019
24 October 2019 SeerPharma is excited to publish the final issue of our Journal for 2019. With articles on our activities with customers and attendance at major industry events in the APAC region. We hope you find something…
FDA grants Orphan Drug Designation for NNZ-2591 to treat Phelan-McDermid syndrome and Pitt Hopkins syndrome
16 October Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of each of Phelan-McDermid syndrome and Pitt Hopkins syndrome.…
CSIROscope: How do you mend a broken heart?
16 October 2019 By Ali Green Sunday was World Heart Day and we celebrated in true CSIRO style – with science and technology. In a world-first, a man in the US received a replacement heart valve. It was…
Bionics Institute receives comprehensive ISO 9001 accreditation covering all operations, research and development processes
16 October 2019 The Bionics Institute is the first and only Australian Medical Research Institute (MRI) to receive a comprehensive ISO 9001 accreditation covering all operations, research and development processes. This accreditation reinforces the Bionics Institutes commitment to…
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
15 October 2019 SYDNEY, AUSTRALIA – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces mature positive efficacy data from its TACTI-mel Phase…
Tim Oldham Appointed as Chief Executive Officer of AdAlta Ltd
9.10.2019 MELBOURNE Australia: The Board of AdAlta Limited (ASX:1AD), is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director. Dr Oldham has extensive skills and expertise over…
Smileyscope secures a prominent Silicon Valley investor
9 October 2019 August and September have been landmark months for Smileyscope. We welcome our largest investor to date, and are closing a funding round which will allow us to grow rapidly through the next 18 months. Our…
Opthea To Present at the Ophthalmology Innovation Summit in San Francisco
4 October 2019 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at the Ophthalmology Innovation…
Cartherics Pty Ltd to Present at 2019 Cell & Gene Meeting on the Mesa
1 October 2019 Melbourne, Australia, – Cartherics Pty Ltd announced today that Professor Richard Boyd, Chief Scientific Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California.…
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
26 September 2019 • Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2 • Recruitment of cohort 2 of Part A…
